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ABSTRACT* 
  
Often few alternative anesthetics for exotic species are available, due to the small numbers 
of these animals used in research. In this study, we evaluated the depth and duration of anesthesia 
in Xenopus laevis after their immersion in 3 doses of etomidate (15, 22.5, and 30 mg/L) and in 3 
doses of benzocaine (0.1%, 0.5%, and 1%) compared with the ‘gold standard,’ tricaine 
methanesulfonate (MS222; 2 g/L). We then chose an optimal dose for each alternative anesthetic 
according to induction time, duration of surgical plane, and time to complete recovery. The optimal 
etomidate and benzocaine doses (22.5 mg/L and 0.1%, respectively) as well as the MS222 dose 
were then used to achieve a surgical plane of anesthesia, with the addition of flunixin meglumine 
(25 or 50 mg/kg) administered in the dorsal lymph sac at the completion of mock oocyte harvest. 
Efficacy of the analgesic was assessed at 1, 3, 6, and 24 h postoperatively by using acetic acid 
testing (AAT). Histology of the liver, kidney, and tissues surrounding the dorsal lymph sac was 
performed at day 3, 14, and 28 in each group of animals.  
Mild to moderate myocyte degeneration and necrosis were present in tissues surrounding 
the dorsal lymph sac at both flunixin meglumine doses after etomidate and benzocaine anesthesia. 
In addition, the 50-mg/kg dose of flunixin meglumine resulted in the death of 5 of the 12 frogs 
within 24 h, despite an otherwise uneventful anesthetic recovery. In conclusion, benzocaine and 
etomidate offer alternative anesthetic regimens, according to typical requirements for an anesthetic 
event. Flunixin meglumine at the 25-mg/ kg dose provided analgesic relief at the latest time point 
during etomidate dosage and at all time points during benzocaine dosage, but further 
characterization is warranted regarding long-term or repeated analgesic administration. 
*Reprinted with permission from “Comparison of Etomidate, Benzocaine, and MS222 Anesthesia with and without Subsequent 
Flunixin Meglumine Analgesia in African Clawed Frogs (Xenopus laevis)” by B. Smith, K. Vail, G. Carroll, M. Taylor, N. 
Jeffery, T. Vemulapalli, J. Elliott (2018). J Am Assoc Lab Anim Sci, 57(2), 202-209. Copyright 2018 
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CHAPTER I 
 INTRODUCTION: WORKING WITH XENOPUS LAEVIS IN THE LABORATORY 
ANIMAL ENVIRONMENT 
 African clawed frogs (Xenopus laevis) were originally used in the development of the 
human pregnancy assay; however, their use as one of the major amphibians in the laboratory 
environment has been attributed to a simplified version of reproduction as compared to mammals. 
Not only do they possess the ability to yield large numbers of oocytes within a short period of 
time, they can be manipulated to super ovulate with the use of pregnant mare serum and human 
chorionic gonadotropin to produce eggs year round.4 This can be achieved through not only normal 
mating, but also artificial fertilization. With a quick hatching time of 3 days, the offspring can be 
easily visually monitored for any obvious genetic manipulations or abnormalities. These offspring 
are then used 5 hours post-fertilization for the FETAX assay (frog embryo teratogenesis assay: 
Xenopus). This assay will evaluate effective and lethal concentrations of test substances, looking 
at parameters such as developmental stages, malformations of the major organs, and biochemical 
markers, among others.1, 4 
 In their natural setting, Xenopus can be considered a hardy species; surviving in a wide 
variety of habitats from rivers to swamps, with wide temperature variation and the ability to breed 
in not only acidic and alkaline water, but also tolerate salt water for short periods of time. Although 
they prefer temperatures in the 21-22°C range, they possess the ability to survive in ice covered 
ponds, dig mud pits to cool when the temperature is in excess of 30°C, and estivate in periods of 
drought.2,5 
While a variety of housing material in the laboratory setting can be used, such as fiberglass, 
glass, plastic or stainless steel tanks, Xenopus avoid brightly lit areas and prefer some sort of cover, 
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such as artificial vegetation. In the wild, they typically inhabit opaque or murky water.2,5 Thus, in 
the laboratory, static housing is an option for use, however it does require more intensive cage 
cleaning and labor time. As an alternative option, flow-through or recirculating tanks can be used, 
but water parameters must be monitored more frequently depending on the source of the water. 
Toxic elements present in municipal (‘tap’) water may include chlorine, chloramine, nitrite, nitrate, 
ammonia, iodine, copper, lead, zinc, PVC adhesives, detergents, disinfectants and pesticides. 
Another common environmental parameter that can affect the health status of the frogs is based 
on the oxygen saturation of the water, which during times of super saturation can lead to a disease 
commonly known as gas bubble disease. This leads to excess oxygen accumulation in the 
vasculature eventually resulting in capillary hemorrhage with buoyancy issues, petechial 
hemorrhage and loss of the mucous layer, and often times requires euthanasia.5 
Another critical factor in housing and maintaining a colony of animals pertains to their diet. 
In the wild, Xenopus will consume aquatic invertebrates, small crustaceans, insects, and carcasses 
of animals while using olfaction to detect their food.5 Group feeding can become aggressive in 
either the natural or laboratory setting, so proper housing density should be maintained, at a 
recommended 1 adult frog per 2 liters of water according to The Guide for the Care and Use of 
Laboratory Animals.3 In the research environment, Xenopus tadpoles are efficient filter feeders, 
and beginning on day 5, a powdered diet can be provided twice per week, eventually switching 
over to pellets with increasing age. Due to their smaller size, it is initially possible to maintain the 
young at a higher stocking density of 50 per liter, although as they grow, they must be separated 
to avoid overcrowding. With regards to the adults, it is difficult to feed the same diet that would 
be obtained in the wild, but formulated diets have been created to provide for their dietary needs 
including salmon chow, trout chow, or Frog Brittle (1 g/frog). Additional food enrichment can 
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include earthworms, mealworms, chick embryos, Tubifex worms, goldfish and crickets. 
Mealworms and crickets should be used with caution as they contain chitin, which can cause 
intestinal blockage. The frogs should remain undisturbed for at least one hour after feeding to 
prevent regurgitation.2,5 
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CHAPTER II 
COMPARISON OF ETOMIDATE, BENZOCAINE, AND MS222 ANESTHESIA WITH AND  
 
WITHOUT SUBSEQUENT FLUNIXIN MEGLUMINE ANALGESIA IN AFRICAN  
 
CLAWED FROGS (XENOPUS LAEVIS)* 
 
II. 1. Background 
 
African clawed frogs (Xenopus laevis) are a common amphibian species in the research 
environment due to their ease of maintenance, hardiness, adaptability to various housing 
arrangements, short generation times, and high yield of genetic material.25 Traditionally, female 
Xenopus have been used extensively for oocyte collection, gonadectomized male frogs have been 
used to study degeneration of the vocal pathway, and both sexes have been used to study cardiac 
morphology, cranial osteogenesis and suture morphology for craniofacial development, spinal 
cord regeneration, and androgen regulation of the neuromuscular junction structure and 
function.1,2,4,29,41  
The necessity to manipulate or collect samples from Xenopus frogs can cause difficulties 
during handling as a result of their slippery mucous layer, consequently creating undue stress on 
the animals. The addition of chemical restraint not only facilitates the situation for handlers but 
also enhances the welfare of the animals. Chemical restraint in amphibians, ranging from 
sedation to surgical plane anesthesia, can be achieved through a variety of routes, including 
immersion, topical, injectable, and inhalant.22,35,40 Although tricaine methanesulfonate (MS222), 
a benzocaine derivative, is considered the ‘gold standard’ as an immersion anesthetic for X.  
laevis,18,21 its various disadvantages, including respiratory irritation in personnel handling the 
*Reprinted with permission from “Comparison of Etomidate, Benzocaine, and MS222 Anesthesia with and without Subsequent 
Flunixin Meglumine Analgesia in African Clawed Frogs (Xenopus laevis)” by B. Smith, K. Vail, G. Carroll, M. Taylor, N. 
Jeffery, T. Vemulapalli, J. Elliott (2018). J Am Assoc Lab Anim Sci, 57(2), 202-209. Copyright 2018 
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powdered form and the need to buffer the solution,14,22,26,37 prompt the consideration of 
alternative anesthetic regimens.  
Examples of alternative anesthetics previously explored in Xenopus include benzocaine 
gel, ketamine, eugenol (clove oil), isoflurane, propofol, medetomidine, and dexmedetomidine. 
Compared with MS222, benzocaine gel in amphibians produces a faster induction and a 
prolonged recovery, and its effects are weight-dependent, such that increased body weight 
resulted in a longer induction time.21 Ketamine can provide long-lasting anesthesia, ranging from 
12 to 18 h, but published literature questions its analgesic properties in African clawed 
frogs.14,17,22  
Eugenol, a clove-oil extract, has the ability to produce short-term anesthesia but is 
weight-dependent and cardiodepressive.12,16,22 Bubbling isoflurane inhalant in tank water is 
unsuccessful.40 Topical application of isoflurane is the most effective form to administer 
isoflurane; however skin irritation and variation in time to surgical plane and duration of 
anesthesia have been observed.30 Propofol is unsafe to use in Xenopus,14,15,40 and α2 agonists 
such as medetomidine and dexmedetomidine are ineffective in this species.11,40  
Other anesthetic options to explore in Xenopus include drugs such as etomidate, benzocaine 
in solution, and alfaxalone. Etomidate, an imidazole-derivative anesthetic and hypnotic, has been 
used for anesthesia of Xenopus tadpoles28 and in oriental fire-bellied toads (Bombina orientalis).8 
Benzocaine in solution has been used in field studies, but a dose for X. laevis has not been 
published.36 Alfaxalone has been studied in bullfrogs (Lithobates catesbeiana) and did not produce 
immobilization or anesthesia.27 Although alfaxalone is a possible alternative anesthetic for 
Xenopus, its classification as a schedule IV controlled substance renders it difficult and costly to 
obtain.10  
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The detection of pain in amphibians is difficult, and whether species without a cerebral or 
limbic cortex are able to experience pain has been debated.33 The primary mechanism of 
nociception in the spinal cord of amphibians is similar to that of mammals and fish, and the pain 
neurotransmitters and endogenous opioid peptides in the spinal cord are similar as well.23,32,39 
These findings support the idea that amphibians and mammals experience nociception similarly. 
As with other species, distinguishing whether a frog’s response to a noxious stimulus is a clinical 
finding indicating stress or actual pain, both of which should be treated, is essential.6 Although 
opioid and nonopioid analgesia have been studied more extensively in leopard frogs (Rana 
pipiens) by using the acetic acid test (AAT),24,34 providing and assessing analgesia in Xenopus is 
an important requirement for the welfare of the animals, especially given their increasing 
numbers in the research setting.13  
Although an extensive list of analgesic choices exists, including drugs such as morphine, 
butorphanol, and buprenorphine, flunixin meglumine may provide better analgesia and has the 
additional benefit of being a nonscheduled substance.7,31 Flunixin meglumine (trade name 
Banamine), is a NSAID that is most often used in agricultural animals. A dose of 25 mg/kg 
administered in the dorsal lymph sac of X. laevis achieved significant analgesic effects in as little 
as 5 h after administration; in addition, the authors recommended further characterization and 
exploration of any adverse side effects.7  
In the current study, we had 2 goals. The first was to determine whether etomidate or 
benzocaine produce similar anesthetic events to those of MS222 in African clawed frogs. 
Providing alternative anesthetic regimens that avoid the occupational health and safety risks of 
MS222 and the patient risks associated with incorrectly buffered solutions (particularly skin 
irritation and inflammation) is key to achieving this goal. The second goal was to further 
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characterize the analgesic properties of flunixin meglumine administered to Xenopus frogs at 
increased dosages and when used in combination with etomidate, benzocaine, or MS222. In 
addition, we used histology to examine whether these anesthetic regimens were associated with 
significant pathology.  
II. 2. Materials and Methods  
II. 2.1 Animals 
All work was performed on an IACUC-approved protocol at an AAALAC-accredited 
program at Texas A & M University. Adult male (n = 36; weight, 22 to 59 g) and female (n = 36; 
weight, 24 to 130 g) African clawed frogs (X. laevis) older than 1 y were obtained from an inhouse 
breeding program. The frogs were determined to be in good health by physical exam (American 
Association of Anesthesiologists score of 1)9 and had participated in no confounding studies prior 
to investigation. The frogs were randomly allocated into 12 groups of 6 frogs each; 7 groups (total, 
42 frogs) were used to investigate each anesthetic regimen in the absence of analgesic relief, 
whereas the remaining 5 groups (total, 30 frogs) received the optimal doses of each anesthetic as 
determined in the first experiment and were used to further characterize flunixin meglumine 
analgesia. Each frog underwent a single anesthetic event, which included the creation of a surgical 
incision in the lower abdomen.  
II. 2. 2 Housing 
Frogs were group-housed (Xenoplus Stand Alone housing systems, Tecniplast, West 
Chester, PA) at 5 to 8 frogs per tank prior to the study and after surgical incisions had healed. 
Initially frogs were returned to group housing after complete recovery from anesthesia, but due 
to incision site complications during group housing after experimental manipulation, frogs were 
singly housed for the remainder of the experiment in static tanks, with weekly water changes and 
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enrichment provided in the form of an opaque yellow plastic lid that they could use for shelter. 
The room was set on a 12:12-h light:dark cycle, with a room temperature of 68 to 72 °F (20 to 22 
°C). The water was obtained from the municipal supply and filtered by using UV light, a carbon 
filter, and a biofilter. The system water was maintained at 68 to 72 °F (20 to 22 °C), with a pH of 
6.2 to 8.5, conductivity ranging from 500 to 3000 μS, and monitoring for the presence of 
ammonia and chlorine. Frogs were fed a commercially available pelleted diet (Frog Brittle [45% 
protein], Nasco, Fort Atkinson, WI) 3 times each week, and uneaten food was removed from the 
tanks daily.  
II. 2. 3 Anesthetic doses 
In the initial portion of the study, 36 frogs (6 per group) were immersed in the following 
doses of benzocaine (0.1%, 0.5%, 1%) and etomidate (15, 22.5, 30 mg/L) to determine the 
optimal anesthetic dose to obtain an adequate surgical anesthetic plane for each anesthetic, 
without prolonged immersion time or the time until complete recovery. Another group, 
containing 6 frogs, was anesthetized with MS222 at 2.0 g/L to serve as the control for comparing 
the time until induction, duration of surgical-plane anesthesia, and time to complete recovery.  
Water from the recirculating system was used as the vehicle for each anesthetic 
immersion. The pH of each solution was evaluated by using pH paper (Hydrion, Micro Essential, 
Brooklyn, NY), and solutions were titrated with sodium bicarbonate as needed to reach a neutral 
pH of 7.0. MS222 (Sigma Aldrich, St Louis, MO) was weighed as a solid form in a hard-ducted 
fume hood by using respiratory protection and gloves to avoid skin irritation before being 
dissolved in tank water.36 Benzocaine (Sigma Aldrich) was weighed in its solid form and then 
dissolved in 100% ethyl alcohol before being diluted in tank water to its final concentrations.38 
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Etomidate (2 mg/mL, Hospira, Lake Forest, IL) was formulated as a liquid, and it was mixed 
directly into the tank water to create the appropriate dosages.8  
Each frog was submerged in a plastic container filled with the appropriate drug and at the 
correct concentration until it reached a surgical plane of anesthesia. The onset of surgical-plane 
anesthesia was defined as the time at which the frog could no longer maintain a righting or 
withdrawal reflex. The righting reflex was evaluated by assessing each frog’s ability to turn onto 
its ventrum when placed on its back and was scored from 0 to 3 (0, unable to right itself; 1, weak 
attempt to right itself; 2, strong attempt to right itself but unable to flip over; and 3, able to flip 
itself over). The withdrawal reflex was tested by pinching a phalangeal articulation of the pelvic 
limb with the tips of the anesthetist’s fingers for a maximum of 2 s to evaluate whether the frog 
withdrew the limb; responses were scored from 0 to 2 (0, none; 1, weak; and 2, strong response). 
Reflexes were tested at 1-min intervals until complete loss of both reflexes occurred.  
After reaching a surgical plane of anesthesia, frogs were removed from the anesthetic 
solution, weighed, rinsed with fresh recirculating tank water to move any debris from the 
surgical site, and placed on their dorsum on a wet diaper pad. The depth of anesthesia was 
further evaluated in response to an additional physical stimulus with the creation of a 1- to 2-cm 
full-thickness incision at the lower right quadrant of the ventrum by using a no. 15 scalpel blade. 
No oocytes were removed, nor were the abdominal contents manipulated. A 2-layer closure was 
performed by using 4-0 polydioxanone for the muscle layers, and 4-0 nylon was used to suture 
the skin; both closures were achieved by using a simple interrupted pattern.3  
Anesthetic depth was monitored from the initiation of surgery until complete recovery by 
using a pulse oximeter (Nonin, Model 9847V) to monitor heart rate; the righting and withdrawal 
reflexes were tested at 5-min intervals. Complete recovery was indicated when the righting and 
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withdrawal reflexes both returned to normal (scores of 3 and 2, respectively). Postoperatively, 
once frogs had completely recovered, they were placed in a static tank with a gas bubbler, 
delivering room air, for monitoring. The time from immersion to achieving a surgical plane of 
anesthesia (induction), duration of surgical-plane anesthesia, and duration of anesthesia until 
complete recovery were all recorded.  
Initially animals were monitored daily postoperatively in group housing looking for 
abnormal behavior including floating and reluctance to dive,14 weight loss, decreased appetite, 
inflammation, erythema, infection or wound dehiscence. However, group-housed frogs became 
stressed and reacted negatively, with excessive kicking and activity, in response to daily 
handling involving capture with nets and individual restraint to monitor the incision site; we 
therefore switched to single housing, where daily visual monitoring through the clear tank was 
performed instead. Once the incision site had healed, typically within 10 to 14 d, frogs were 
returned to group housing in the recirculating water system.  
II 2. 4.Flunixin meglumine administration 
For the second portion of the experiment, flunixin meglumine (25 or 50 mg/kg) was 
administered into the right dorsal lymph sac by using a 22-gauge needle immediately after the 
completion of surgery. This portion of the experiment involved 5 groups (n = 6 frogs per group), 
which received either MS222 or etomidate (22.5 mg/L) with either 25 or 50 mg/kg of flunixin 
meglumine or 0.1% benzocaine with 25 mg/kg of flunixin meglumine.  
To test the effectiveness of pain control, AAT was performed at 1, 3, 6, and 24 h after 
complete recovery from anesthesia. Testing consisted of applying a single drop of acetic acid 
from a needleless 1-mL syringe (Terumo) in increasing concentrations to the dorsum of the thigh 
until the frog exhibited a wiping (positive) response to the irritation. Acetic acid was placed for a 
 12 
 
 
 
 
contact time of 3 to 5 s and then rinsed off with tank water. The acetic acid was alternated 
between legs for each increasing dose, at concentrations of 0%, 5%, 10%, 20%, and 50%. 
Responses were scored as either positive or negative for each increasing dose, until a positive 
response occurred or the maximal concentration (50% acetic acid) was reached.15  
II 2.5 Histology 
One frog from each study group was euthanized at 3, 14, and 28 d after surgery, for a 
total of 36 frogs necropsied. Euthanasia was performed by using MS222 overdose (that is, 
exposure to 2 g/L for greater than 20 min) followed by pithing, after which tissues were fixed in 
10% formalin solution. Representative samples including liver, kidney, and tissues surrounding 
the right dorsal lymph sac were processed and evaluated histologically by using hematoxylin and 
eosin staining, with particular attention for abnormalities or effects in the liver, kidney, and right 
dorsal lymph sac tissue where the flunixin meglumine was administered.  
II. 2. 6 Statistics 
Stata 11 for Windows (StataCorp, College Station, TX) was used to perform 
multivariable linear regression, with anesthesia type and frog weight included as independent 
variables. Successful and unsuccessful anesthesia parameters were compared between agents by 
using the χ2 test (with P < 0.05 taken to indicate significant differences).  
The average and 95% confidence interval were calculated for induction time, duration of 
surgical-plane anesthesia, and time to complete recovery by evaluating MS222 as the baseline 
regimen to generate inclusion and exclusion parameters for characterizing etomidate and 
benzocaine doses as comparable anesthetic alternatives. SuperANOVA was used to calculate 1 
SD and to perform 1-way and 2-way ANOVA of the anesthetic parameters, and StatView 4.1 
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was used to perform unpaired t tests to determine whether analgesia affected anesthetic param-
eters when combined with each anesthetic.  
II. 3 Results  
II. 3. 1 Induction time 
Weight influenced induction time (R2 = 0.6817, P = 0.043), on the basis of the 
multivariable linear regression analysis for frogs that did not receive analgesia. However, weight 
did not influence the duration of the surgical plane of anesthesia (R2 = 0.6187, P = 0.552) or 
recovery time (R2 = 0.7612, P = 0.094).  
For MS222, the induction time was 3.6 ± 1.6 min (mean ± 1 SD), with upper and lower 
95% confidence intervals of 2.9 and 4.4 min, respectively; 6 min was the maximal time needed 
to reach a surgical plane of anesthesia. The etomidate doses of 15, 22.5, and 30 mg/L took 26.2 
±16.6, 13.8 ± 4.3, and 7.5 ± 2.5 min, respectively, to reach a surgical plane, whereas the 
benzocaine doses of 0.1%, 0.5%, and 1% took 3.2 ± 0.8, 3.5 ± 0.8, and 2.8 ± 0.8 min, 
respectively, to achieve surgical anesthesia. Relative to the maximal induction time of 6 min for 
MS222, doses of etomidate required a longer immersion time for induction while all doses of 
benzocaine required a shorter immersion time (Figure 1). When comparing induction times of 
anesthetics to MS222 without the administration of analgesia in any frogs, etomidate 15 mg/L 
and etomidate 22.5 mg/L had a statistically significant difference (P < 0.05).  
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Figure 1. Induction time (that is, from the point of immersion into anesthetic solution until complete loss of righting 
and withdrawal reflexes). The dotted line represents the 6-min maximum required for MS222 to induce anesthesia. 
MS222, MS222 at 2 g/L; Et, etomidate at 15, 22.5, or 30 mg/L; B, benzocaine at 0.1%, 0.5%, or 1%. 
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II. 3. 2 Duration of surgical-plane anesthesia 
For MS222, the duration of surgical-plane anesthesia was 27.2 ± 8.1 min, with 95% 
confidence limits of 21.4 and 34.2 min. When the low dose (25 mg/kg) of flunixin meglumine 
was administered with MS222, the surgical-plane time was 15.3 ± 8.2 min, whereas at the high 
dose (50 mg/kg), it was 41.0 ± 5.7 min. Etomidate doses of 15, 22.5, and 30 mg/L without 
flunixin meglumine provided surgical-plane anesthesia for 21.3 ± 11.0, 30.3 ± 26.1, and 69.3 ± 
26.5 min, respectively. With the addition of flunixin meglumine at 25 mg/kg to etomidate 
anesthesia at 22.5 mg/L, surgical-plane anesthesia lasted 34.8 ± 18.4 min, and with the addition 
of 50 mg/kg flunixin meglumine, the duration was 45.0 ± 13.6 min. Benzocaine at 0.1%, 0.5%, 
and 1% without flunixin meglumine provided surgical anesthesia for 38.0 ± 11.0, 63.0 ± 17.0, 
and 72.5 ± 10.2 min, respectively. With the addition of 25 mg/kg flunixin meglumine to 0.1% 
benzocaine anesthesia, surgical anesthesia was 23.7 ± 9.5 min. The average time for mock 
oocyte collection was approximately 10 min (Figure 2).  
Comparing the duration of surgical-plane anesthesia from MS222 with other anesthetics 
in the absence of analgesia revealed statistically significant (P < 0.05) differences for etomidate 
at 30 mg/L and benzocaine at 0.5% and 1.0%. Adding flunixin meglumine after each anesthetic 
(MS222, etomidate 22.5 mg/L, and benzocaine 0.1%) did not significantly change the duration 
of surgical anesthesia for etomidate 22.5 mg/L but prolonged it in the groups that received 
MS222 or benzocaine (P = 0.0305 and P = 0.0361, respectively) compared with the groups 
anesthetized without analgesia.  
 16 
 
 
 
 
 
Figure 2. Duration of surgical anesthesia (that is, righting and withdrawal reflexes remained absent), when an 
abdominal incision was created to perform a mock oocyte harvest. The upper line represents the upper 95% 
confidence limit for MS222 (34 min), whereas the lower line represents the 10-min minimum needed to perform a 
surgical oocyte harvest. Doses of fluixin meglumine (flunixin) are given in mg/kg; doses of etomidate (Et) are given 
in mg/L; doses of benzocaine (B) are given in percentage concentration; and the dose for MS222 was 2 g/L. 
 
 
 
II. 3. 3 Recovery 
Recovery from surgical-plane anesthesia began when a score of 1 was obtained for either 
the righting or withdrawal reflex; complete recovery was achieved when frogs scored 2 for the 
withdrawal reflex and 3 for the righting reflex. The recovery time for frogs anesthetized with 
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MS222 was 15.8 ± 16.8 min (95% confidence interval, 9.5 to 24 min). With the addition of 
flunixin meglumine, the duration of recovery at the low dose (25 mg/kg) was 14.7 ± 6.7 min and 
at the high dose (50 mg/kg) was 27.0 ± 14.0 min. Etomidate at 15, 22.5, and 30 mg/L doses 
produced recovery times of 39.0 ± 10.1, 52.3 ± 21.5, and 66.3 ± 8.2 min, respectively. The 
addition of flunixin meglumine at 25 mg/kg to etomidate at 22.5 mg/L gave a recovery time of 
53.2 ± 18.1 min, and adding 50 mg/kg flunixin meglumine to the same concentration of 
etomidate yielded a recovery time of 54.8 ± 8.7 min. Benzocaine at 0.1%, 0.5%, and 1.0% had 
average recovery times of 23.0 ± 7.0, 24.5 ± 8.3, and 24.3 ± 6.6 min, respectively. Addition of 
flunixin meglumine at 25 mg/kg to benzocaine 0.1% anesthesia provided a recovery time of 16.2 
± 3.7 min (Figure 3).  
When we compared the duration of recovery after MS222 in the absence of analgesia 
with those of other study groups, all doses of etomidate showed significantly (P < 0.05) 
prolonged recovery, whereas recovery time did not differ between MS222 and all doses of 
benzocaine without analgesia. The addition of flunixin meglumine to each anesthetic group 
(MS222, etomidate 22.5 mg/L, and benzocaine 0.1%) had no significant effect on recovery time 
compared with each respective anesthetic regimen without analgesia.  
The creation of the abdominal incision had an unexpected adverse consequence during 
the postoperative period, when the frogs reacted negatively to daily handling to monitor body 
weight and the incision site. At approximately 1 wk after surgery, 8 frogs total (1 of the 8 from 
the MS222 group, 2 of the 8 given MS222 and 25 mg/kg flunixin meglumine, 2 of the 8 that 
received etomidate at 15 mg/L, 1 of the 8 in the 22.5-mg/L etomidate group, and 2 of the 8 from 
the 30-mg/L etomidate group) tore out their sutures when excessively kicking to avoid capture in 
their group-housing tank. These 8 frogs were euthanized, and the remaining frogs were housed 
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individually until the incisions had healed (day 10 to 14). Sutures were not removed from the rest 
of the animals, because they shed them from the skin before the end of the study.  
 
 
 
 
 
Figure 3. Recovery time. Surgical-plane anesthesia ended (and the recovery phase began) when the score for either 
the righting or withdrawal reflex was 1 or greater; recovery was complete when frogs scored 2 for the withdrawal 
reflex and 3 for the righting reflex. The dotted line represents the upper 95% confidence limit for MS222 (24 min). 
Doses of fluixin meglumine (flunixin) are given in mg/kg; doses of etomidate (Et) are given in mg/L; doses of 
benzocaine (B) are given in percentage concentration; and the dose for MS222 was 2 g/L. 
 
 
 
II. 3. 4 Flunixin meglumine administration 
The 25-mg/kg dose of flunixin meglumine was well tolerated and showed no adverse 
effects during initial recovery. However, 50 mg/kg caused unexpected death within 24 h of 
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administration in 5 of the 12 frogs, despite an uneventful recovery when anesthetized with 
MS222 or 22.5 mg/L etomidate. Consequently, we did not administer the 50-mg/kg dose of 
flunixin meglumine to frogs anesthetized by using 0.1% benzocaine. Pathology from the affected 
frogs was inconclusive regarding a cause of death; one frog was diagnosed with lymphosarcoma, 
which was considered an incidental finding unrelated to experimental manipulation. Because of 
these complications, we excluded the data for the 50-mg/kg dose of flunixin meglumine from 
further analysis.  
For AAT, a negative response after the application of acetic acid at 10% or greater was 
indicative of effective pain relief for the purposes of this experiment. One frog anesthetized with 
MS222 and given 25 mg/kg flunixin meglumine was euthanized due to complications of acid 
burns from the AAT despite no pain response to the maximal dose of acetic acid. Administration 
of flunixin meglumine was ineffective at providing pain relief when combined with MS222, but 
MS222 alone provided analgesic relief at the 6-h time point. At all of the time points assessed, 
the combination of 0.1% benzocaine and 25 mg/kg of flunixin meglumine provided effective 
pain relief. In addition, the combination of 22.5 mg/L etomidate and 25 mg/kg flunixin 
meglumine appeared to provide pain relief at the 24-h time point (Table 1).  
 
 
 
Table 1. Results of acetic acid testing in frogs (n = 6 per group)  
MS222  MS222 + FM  Etomidate  Etomidate + FM  Benzocaine  Benzocaine + FM  
1 h  1  2  0  0  0  4  
3 h  2  2  1  0  1  4  
6 h  4  2  0  1  0  4  
24 h  2  2  1  4  1  5  
Frogs were anesthetized with either MS222, etomidate (22.5 mg/L), or benzocaine (0.1%) and subsequently did or did not 
receive flunixin meglumine (FM; 25 mg/kg) in the right dorsal lymph sac. Data are reported as the number of animals that 
did not react when ≥10% acetic acid was applied to the back legs at the indicated time points.  
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II. 3. 5  Histology 
In all study groups, liver samples showed mild to moderate diffuse hepatocellular 
vacuolation, and kidneys had mild, multifocal tubular luminal mineral. The lungs of all 
specimens were unremarkable, independent of the anesthetic or analgesic dose. Control groups 
that did not receive flunixin meglumine had no lesions in the skin or skeletal muscle around the 
dorsal lymph sac. At each time point, the benzocaine group that received 25 mg/kg flunixin 
meglumin had myocyte degeneration and necrosis around the dorsal lymph sac (Table 2). In the 
frogs anesthetized with MS222 or etomidate, 25 mg/kg flunixin meglumine did not increase the 
incidence of myocyte degeneration and necrosis, except in the day-3 sample from the group that 
received etomidate 22.5 mg/L, which showed moderate degeneration and necrosis similar to 
those of the frog that received benzocaine 0.1% anesthesia at day 3. The myocytic degeneration 
and tissue necrosis appeared to be transient and resolved over time (Figure 4).  
 
 
Table 2. Histology of the dorsal lymph sac of frogs  
Flunixin meglumine 
(mg/kg)  
Postsurgical day  MS222 (2 g/L)  Etomidate 22.5 mg/L  Benzocaine 0.1%  
0 mg/kg  3  NSL  NSL  NSL  
0 mg/kg  14  NSL  NSL  NSL  
0 mg/kg  28  NSL  NSL  NSL  
25 mg/kg  3  NSL  Moderate, locally 
extensive, 
monophasic myocyte 
degeneration and 
necrosis  
Moderate, locally 
extensive myocyte 
degeneration and 
necrosis; mild, 
multifocal individual 
epithelial cell 
necrosis  
25 mg/kg  14  NSL  NSL  Minimal, chronic, 
locally extensive 
degeneration and 
regeneration  
25 mg/kg  28  NSL  NSL  Mild, subacute, 
locally extensive 
myocyte 
degeneration and 
regeneration  
NSL, no significant lesions 
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Figure 4. Postoperative day 3. Skeletal muscle deep to the right dorsal lymph sac. (A) Normal myocytes adjacent the 
right dorsal lymph sac in a frog given MS222 and 25 mg/kg flunixin meglumine. (B) Degenerate and necrotic 
myocytes (*) in frog that received etomidate at 22.5 mg/L and 25 mg/kg flunixin meglumine. Myocytes are swollen 
and fragmented, with loss of cross striations. (C) Frog anesthetized with benzocaine at 0.1% and 25 mg/kg flunixin 
meglumine exhibits hypereosinophilic, degenerate (arrow) and necrotic, fragmented (*) myocytes. (D) Skin over the 
right dorsal lymph sac. Frog anesthetized with benzocaine 0.1% and 25 mg/kg flunixin meglumine. Basal 
keratinocytes in the skin over the dorsal lymph sac are necrotic with pyknotic nuclei (arrow). The basement membrane 
is intact. Hematoxylin and eosin staining; magnification, 10× (A–C); 40× (D). 
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II. 4 Discussion  
For the first portion of the experiment, the central question addressed was whether any of 
the alternative anesthetic regimens produced anesthesia similar to that of MS222 in Xenopus 
frogs. To do this, the length of induction, duration of surgical plane anesthesia, and time to 
recovery were assessed and compared with MS222 parameters for each anesthetic regimen.  
Body weight influenced induction time, according to the results of the multivariable linear 
regression analysis. This factor is likely related to the absorption of the anesthetic as an effect of 
surface area. It is important to note that although specific differences between sexes were not 
considered, weight was a factor in the induction of anesthesia, and given that female frogs 
typically are larger than male, this sexually dimorphic characteristic could result in the prolonged 
induction time observed. Because surgical incisions are created in both male and female 
Xenopus, we evaluated both sexes to determine whether pain relief could be achieved, but due to 
small sample numbers, specific differences in pain relief between the sexes were not evaluated.  
Rapid methods of induction generally are preferred over slower regimens, and we determined 
that 6 min was the maximal time necessary for MS222 to induce a surgical plane of anesthesia. 
To be considered as generating a similar anesthetic event as MS222, alternative anesthetics 
should achieve an average induction time of 6 min or less. All doses of etomidate took longer 
than 6 min to induce anesthesia in frogs, whereas all doses of benzocaine took less than 6 min; 
however, the average induction time for 30 mg/L etomidate did not differ significantly from 
MS222. Therefore, in terms of a rapid method of induction, benzocaine produces a statistically 
similar induction time as MS222.  
Regarding the duration of surgical-plane anesthesia, the mean time for MS222 was 27.8 
min, with a 95% confidence interval of 21.5 to 34.2 min. However, 10 min was required on 
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average to complete the surgical oocyte harvest procedure, given the skill level and experience of 
the surgeon. Therefore, we chose 10 min as the minimal duration of surgical anesthesia 
necessary. All doses of benzocaine and etomidate—in the absence of flunixin meglumine—met 
this criterion. In addition, with increasing doses of etomidate and benzocaine, the average 
duration of surgical-plane anesthesia increased as well. However, when compared with the 
duration of surgical-plane anesthesia from MS222, after using 30 mg/L etomidate or 0.5% or 1% 
benzocaine, it was significantly longer and therefore potentially beneficial for procedures 
requiring an extended surgical time. Consequently, depending on the type of experiment and the 
duration of surgical-plane anesthesia required, various alternative anesthetic regimens could be 
used to achieve longer or shorter periods of surgical-plane anesthesia.  
Extended recovery time is not usually desirable when anesthetizing animals, both for the 
health of the animal and for reasons of managerial efficiency. When calculating the length of 
recovery, the upper 95% confidence interval for frogs to recover from MS222 anesthesia was 24 
min, which we used as the criterion for comparison. The average time for recovery from 22.5 
mg/L etomidate was almost double the 24-min limit, whereas recovery after 0.1% benzocaine 
was shorter than the 24-min limit. All doses of etomidate produced significantly longer recovery 
periods than that from MS222, whereas recovery time after all benzocaine did not differ 
significantly from that for MS222. Therefore, when choosing an anesthetic according to recovery 
time, benzocaine is similar to MS222.  
To determine if the alternative anesthetics tested produced an overall anesthetic event 
similar or superior to MS222, the anesthetic had to qualify as having all 3 parameters consisting 
of rapid induction time, duration of surgical plane anesthesia, and recovery time within their 
respective optimal ranges. Benzocaine 0.1% was the only anesthetic to not have any statistically 
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significant differences within these parameters. Both of the other doses of benzocaine, 0.5% and 
1%, produced a similar quick induction and recovery time, but the surgical plane time was 
significantly longer as compared with MS222, which could be considered for experiments 
requiring an extended duration of surgical plane anesthesia.  
Etomidate at 15 and 22.5 mg/L had significantly longer induction times but similar 
durations of surgical-plane anesthesia compared with MS222, whereas 30 mg/L etomidate had a 
similar induction time to MS222 but a prolonged period of surgical plane anesthesia. At all 3 
doses of etomidate, recovery time was significantly prolonged compared with MS222. In the 
context of experiments in which multiple frogs require oocyte harvesting within a short time 
period (for example, a single day), etomidate is not a preferable method of anesthesia, because its 
prolonged recovery period is undesirable.  
We considered all of these parameters when determining the doses of etomidate and 
benzocaine to use in the second portion of the experiment. We chose 0.1% benzocaine because 
all anesthetic parameters did not differ significantly when compared with MS222. When 
determining the etomidate dose, we chose 22.5 mg/L because despite having a prolonged 
induction time compared with MS222, it was quicker than that for the 15 mg/L dose, and 30 
mg/L etomidate produced a significantly longer duration of surgical-plane anesthesia than that 
for MS222.  
We then wanted to determine whether postoperative NSAID administration provided 
prolonged anesthesia and whether the type of anesthesia interacted with the analgesic effects. We 
restricted the test to include only those agents with similar durations of surgical-plane anesthesia, 
induction, and recovery as MS222. The lower NSAID dose significantly decreased the duration 
of surgical-plane anesthesia due to MS222, whereas the higher dose prolonged it. However, the 
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addition of flunixin meglumine at either dose did not significantly affect the average duration of 
surgical plane anesthesia while using etomidate. As noted with MS222, low-dose flunixin 
meglumine decreased the duration of surgical-plane anesthesia for frogs anesthetized with 0.1% 
benzocaine as compared with those that did not receive analgesia. The exact mechanism of this 
analgesia-associated alteration in the duration of surgical-plane anesthesia is unknown and 
warrants additional studies.  
We were concerned that, due to synergistic effects between analgesia and anesthesia, 
recovery from anesthesia might be prolonged with analgesia or the frogs might not recover from 
anesthesia at all.13 All frogs recovered initially, regardless of the type of anesthesia or the dose 
of flunixin meglumine used.  
The effect of flunixin meglamine is interesting in that it appeared to be affected by the 
type of anesthetic agent used. With MS222 alone, the only negative response during AAT in the 
absence of analgesia occurred at the 6-h time point, and the addition of low-dose (25 mg/kg) 
flunixin meglumine did not appear to provide appropriate pain relief. When etomidate was used 
for anesthesia, the analgesic effect of flunixin meglamine at the 25-mg/kg dose was delayed until 
the 24-h time point, likely because of residual effects of etomidate.7 However, with the use of 
benzocaine for anesthesia, the addition of flunixin meglumine at 25 mg/kg provided analgesia at 
all time points, but in only 4 of the 6 frogs at each of the 1-, 3-, and 6-h time points and in 5 of 
the 6 animals at the 24-h time point. These variable effects may be due to synergism (or lack 
thereof) with the anesthetic agent used, individual animal metabolism, or variability in 
absorption from the lymph sac. Given the observed variation in response to the administration of 
flunixin meglumine, we do not consider it an effective postoperative analgesic for African 
clawed frogs without further studies, such as pharmacokinetic analyses.  
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Because of unexpected mortality after the administration of 50 mg/kg flunixin 
meglumine, all data from the frogs that received that dose were excluded from further 
calculations. Although all of the frogs in these groups recovered from anesthesia uneventfully, 5 
of the 12 were found dead in less than 24 h, and some in as little as 6 h. In addition, many of 
these frogs received the maximal concentration of acetic acid (50% solution) during AAT, and 
some of these animals showed no response to this dose, thus indicating that flunixin meglumine 
may have provided adequate pain relief. Therefore, toxicity due to the increased acetic acid 
levels or high flunixin meglumine concentration may have been factors contributing to the deaths 
of these frogs. However, pathology results from these frogs were inconclusive in regard to the 
exact causes of death after flunixin meglumine administration.  
In consideration of the histologic findings, the administration of flunixin meglumine was 
relatively safe, with mild effects only at the site of administration and no adverse effects in kidney 
or liver samples from any study group. The hepatocellular vacuolation and tubular luminal material 
in kidney specimens were not clinically significant and are an incidental finding in African clawed 
frogs. In addition, myocyte degeneration and necrosis of tissues surrounding the dorsal lymph sac 
seemed more likely when the NSAID was administered to frogs that received 0.1% benzocaine 
compared with MS222 or etomidate. However, these lesions were minimal and resolved over time.  
The 8 frogs that were removed from the study postoperatively due to self-induced trauma at the 
incision site resulted in individual housing of all other frogs until incision sites had healed 
(approximately 14 d postoperatively). When the frogs tore their incision sites, the ligatures 
remained intact, indicating that the lesions were not due to dehiscence but to excessive force 
exerted by the frogs. The change in housing and decreased handling effectively prevented the 
removal of additional frogs from the study.  
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Because AAT is commonly used in amphibians, especially frogs, we anticipated no skin 
irritation in our animals, providing the test was performed correctly; in testing the pain response, 
acetic acid should cause only minor annoyance to encourage the frog (if conscious) to wipe its 
leg. In this study, the high doses of acetic acid disrupted the mucous layer, such that skin 
irritation and lesions occurred in multiple frogs. An alternative testing method for pain response 
involves the use of the Hargreaves apparatus, which involves placing a hindleg on a plate that 
heats up to elicit a response to a noxious stimulus.19 This apparatus was unavailable for the 
current study.  
In consideration of the 3Rs—reduction, replacement, and refinement—the creation of the 
incision during the determination of adequate anesthetic levels served as a control for the 
characterization of the effectiveness of flunixin meglumine in frogs. This strategy thus reduced 
the number of animals needed for the experiment.20  
In conclusion, etomidate and benzocaine offer MS222-comparable alternative anesthetic 
regimens for Xenopus frogs, depending on the specific anesthetic criteria required for a given 
experiment. Benzocaine at 0.1% was the only anesthetic regimen that did not induce significant 
differences in induction time, duration of surgical-plane anesthesia, and recovery time when 
compared with MS222. However, when 25 mg/kg flunixin meglumine was added to the 0.1% 
benzocaine anesthetic regimen, myocyte degeneration and necrosis of tissues surrounding the 
dorsal lymph sac was increased as compared with the same analgesic dose combined with MS222. 
Low-dose flunixin meglumine (25 mg/kg) appears relatively safe in light of the lack of negative 
clinical signs and only minor histologic changes. However further studies examining additional 
doses between 25 and 50 mg/kg, the specific time points at which therapeutic levels are achieved, 
and testing at time points greater than 24 h are warranted to determine the long-term efficacy of 
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flunixin meglumine as an effective analgesic in African clawed frogs. High doses of flunixin 
meglumine (50 mg/kg or greater) do not appear safe in Xenopus frogs, in light of the associated 
high fatality rates in our experiment. 
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CHAPTER III 
 CONCLUSION 
Working with and handling Xenopus can be difficult due to a variety of factors, most 
notably their slippery mucous layer, creating unnecessary stress and inhibiting their welfare. 
Although they may be observed in their primary enclosure for indicators of their health status such 
as attitude, posture, equilibrium, and for the presence of ulcerations, abrasions, feces or vomit, it 
is often necessary to remove them for further evaluation. In addition to a basic physical 
examination, diagnostics such as fecal cultures, impression smears, skin scrapings, biopsies, 
abdominocentesis, and radiology may be warranted.13 With that in mind, chemical restraint can be 
added to ease the handling process and avoid injuring the animals. Many of the forms of chemical 
restraint can be used on a continuum of sedation, anesthesia and eventually euthanasia, depending 
on the route and final concentration.10,19 MS222 remains the gold standard within the laboratory 
animal setting, but viable alternatives such as etomidate and benzocaine in solution now exist 
depending on the requirements needed for an anesthetic protocol. 
Of greater concern related to distress is the use and proven efficacy of analgesic regimes 
and the alleviation of pain if conscious perception of pain exists in amphibians. Such evidence is 
sorely lacking for Xenopus even though they are one of the most frequently used amphibians in 
the research setting. One of the major factors in this problem is that it has not been clearly defined 
as to whether Xenopus, or amphibians in general, truly experience pain. Indications and causes of 
possible pain or distress in this species include floating and reluctance to dive,6 weight loss, 
decreased appetite, inflammation, erythema, and infection or wound dehiscence, which can be 
similarly observed in other higher species such as cats and dogs. In order to determine if 
amphibians experience pain, the difference between nociception, or the noxious stimuli that is 
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encoded into a neural impulse and send to the brain, and pain, or the cognitive and emotive 
interpretation of sensation as ‘hurt’ or unpleasant stimuli, must be examined.11 
In the nociceptive pathway, transduction, or the process converting a noxious thermal, 
mechanical or chemical stimuli into an action potential occurs. The action potential is propagated 
by neurons to the spinal cord in a process known as transmission. As such, the afferent nociceptive 
pathway in amphibians is similar to that in mammals, where transmission is achieved in 
amphibians consisting of three types of fibers; large, heavily myelinated A fibers; small, thinly 
myelinated B fibers; and small, unmyelinated C fibers corresponding to the somatic sensory 
afferent Aβ, Aδ and C fibers in mammals.16 The thalamus, also present in amphibians, plays a key 
role in receiving and integrating spinal nociceptive input which then projects that information to 
the cortical and subcortical areas of the brain.14 The signals are then modulated from the primary 
afferent fibers to be inhibited or amplified.  However, due to their lack of a cerebral or limbic 
cortex, it is possible that amphibians do not ‘perceive’ what is considered pain as do higher order 
animals which possess intact cerebral or limbic cortexes.17 
Additionally, amphibians have pain-signaling neurotransmitters such as substance P and 
glutamate released in the dorsal horn of the spinal cord, and endorphinergic neurons which release 
met-enkephalin, an endogenous opioid that inhibits the release of substance P and decreases the 
firing of the second-order pain neurons. These substances, in addition to opioid receptors are 
present in both amphibians and mammals, indicating that it is possible for amphibians to 
experience pain as higher order mammals do.16 Conversely, endorphins and opioid receptors can 
be found in organisms with limited nervous systems, such as a cockroach or snail, so the presence 
of such factors still does not definitively indicate that pain is perceived in species such as the 
Xenopus.17 
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Physiologic changes can also be evaluated to help determine if pain is in fact present, as a 
result of disturbances to the hypothalamic pituitary axis. Pain can cause significant changes in the 
cardiovascular, pulmonary, endocrine and autonomic nervous system. Physiologic responses to 
acute pain include increases in heart rate, blood pressure, cardiac output and systemic vascular 
resistance in addition to a decrease in parameters such as tidal volume and residual capacity leading 
to a ventilation-perfusion mismatch resulting in hypoxemia and hypercarbia. In other species, 
glucose intolerance can occur, as well as decreased reproductive function and sleep disturbances. 
Xenopus also produce corticosterone in response to stress, which could also be measured as a 
possible indicator of stress or pain.9 
It is often assumed that if an inciting cause creates pain in a human, it is reasonable to 
expect that it will cause pain in another animal. Despite the fact that amphibians may not precisely 
experience pain in the way that humans do, if they experience stress or pain, both factors, 
independent of each other should be treated through chemical, environmental and behavioral 
modification.1,5 This can include alterations to the immediate environment, and in cases such as 
the Xenopus, the water quality or provision of enrichment, and group or individual housing based 
on the needs of the animal. If the administration of drugs are provided, it should be done with 
caution as there is limited information on the effects in Xenopus, as well as unknown effects on 
research data, although the benefit to animal welfare may outweigh the negative possible impact 
during an experiment. 
Traditional analgesics in other species are most often multimodal with a combination of a 
non-steroidal anti-inflammatory and the administration of an opioid. Although effective, opioids 
are scheduled substances that are controlled, making access to them difficult, and they can have 
negative side effects such as cardiovascular depression, gastrointestinal distress, and in instances 
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such as with the use of buprenorphine in rats, pica can also be a consequence.2,4,15 With the 
administration of opioids in Xenopus specifically, there is concern that sedation could result in 
drowning of the animal due to their exclusively aquatic environment. However, opioids do present 
the option of reversal with substances such as naloxone or naltrexone, and are commonly used and 
are efficacious in a wide variety of species. While non-steroidal anti-inflammatories are easier to 
access and less costly than many opioids, they do still have negative side effects such as increased 
gastrointestinal complications including ulcers, as well as renal and cardiovascular 
complications.20 
In a recent publication by Coble, et. al, the use of non-steroidal anti-inflammatories, opioids 
and alpha-2 agonists were compared using meloxicam and flunixin meglumine, morphine sulfate, 
and xylazine hydrochloride, respectively, for analgesic potential in Xenopus. The authors 
concluded that flunixin meglumine, the non-steroidal anti-inflammatory commonly used in 
agricultural animals, showed the most potential for pain relief in this amphibian species, but 
additional studies were warranted.3 As such, flunixin meglumine was the basis for the study 
described in chapter 2 of this manuscript.  
To further evaluate the effectiveness of the flunixin meglumine, time periods greater than 
24 hours are needed as it was noted that effects correlating to analgesic efficacy were only observed 
at later time points when administered after MS222 or etomidate anesthesia. It is possible that the 
breakdown metabolites are the cause of the later analgesic effects, which could result in analgesia 
lasting longer than 24 hours.  If the analgesic needs time to break down before effects are observed, 
the analgesic could be administered prior to a planned surgical or expected painful event so that 
effective pain relief could be achieved such that animals receive immediate relief when needed, 
and not delayed for hours. It is also important to note that Xenopus may not contain enzymes that 
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break down flunixin meglumine efficiently, although at this time, it may still be the most beneficial 
analgesic. 
In order to facilitate this to determine when the analgesic actually takes effect, 
pharmacokinetic studies should be performed looking at the peak plasma concentrations and to 
determine a minimal plasma level that is required for analgesic efficacy. The pharmacokinetic 
study could also help explain the unexpected deaths observed after the administration of the higher 
dose of flunixin meglumine (50 mg/kg). While flunixin meglumine is relatively safe, it could have 
caused excessive damage to the kidneys, or it could have entered the nervous system resulting in 
cardiac depression. If the analgesic needs time to break down before becoming toxic at the 
increased dose, it could clarify why all the frogs that died unexpectedly had recovered from 
anesthesia uneventfully. Although necropsies and histology were performed on those 5 frogs, there 
was no conclusive reason for their deaths.  
Lastly, the ability to detect pain in Xenopus is not always specific or easily observed. 
While monitoring signs such as body weight and appetite are useful, there is not a behavioral 
ethogram or standardized pain assessment test such as the grimace scale or nest building scale 
that have been created for common laboratory animals such as mice and rats. The acetic acid test 
is performed in amphibians to determine pain levels, however it can cause detrimental effects to 
the mucous layer and may not correlate as efficiently as thought to the perceived pain in this 
species.12,18 Other tests exist such as the Hargreaves apparatus,7 which uses a heat source to incite 
pain, or von Frey filaments,8 which uses varying sizes of fibers to test for mechanical or pressure 
sensitivity. Both tests can be applied to the webbed feet assessing nociception, while not causing 
the lesions that can result from the acetic acid testing, offering viable alternatives that improve 
the welfare of the frogs. 
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